(Reuters Health)—People with thumb-base osteoarthritis (OA) who receive a combination of conservative treatments, including education in self-management, ergonomics and hand exercises, may experience clinically meaningful improvements in hand function, a study suggests. Researchers randomized 204 people with thumb-base OA (1:1) to receive education on self-management and ergonomics alone (comparator) or in combination with a base-of-thumb…
Search results for: hospital
Total Knee Replacement Cost-Effective, Even with Obesity & Comorbidities
(Reuters Health)—Total knee replacement surgery can be a cost-effective procedure for patients with severe obesity and osteoarthritis (OA), even when they also have comorbidities such as cardiovascular disease or type 2 diabetes, a new study suggests. Researchers did a cost-benefit analysis for two patient populations (over 65 years, and age 50 to 65) who had…
COVID-19 Vaccination Strategies Suggested for Patients on Anti-Rheumatic Immunosuppressive Therapy
NEW YORK (Reuters Health)—U.K. experts propose evidence-based management strategies for rheumatology patients on immunosuppressive therapy, including delaying/postponing rituximab, as appropriate. “The aim of this viewpoint article is to outline the existing data on the effect of anti-rheumatic therapy on vaccine responses in patients with inflammatory arthritis and to formulate a possible pragmatic strategy for the…
FDA Approves Tocilizumab to Treat Systemic Sclerosis-Associated ILD
Subcutaneous tocilizumab is the first biologic agent approved by the FDA treat patients with systemic sclerosis-associated interstitial lung disease.
Non-Invasive Vagus Nerve Stimulation Tolerated, Effective for Rheumatoid Arthritis
(Reuters Health)—Non-invasive vagus nerve stimulation is safe and effective as an intervention for rheumatoid arthritis (RA), a small proof-of-concept study suggests. The study enrolled 35 patients with active RA and an inadequate response to therapy with disease-modifying anti-rheumatic drugs (DMARDs). All DMARDS were discontinued four weeks prior to the trial. For the study, all participants…
FDA Approves Belimumab & Voclosporin for Lupus Nephritis
In December, the FDA approved belimumab, the first drug approved to treat lupus nephritis, an historic action that was rapidly followed in January by the approval of a second treatment for lupus nephritis, voclosporin.
Improving Demographic Representation & Equity in Rheumatology Research
A better understanding of knowledge gaps and increased engagement of underrepresented communities are needed to diversify rheumatology patient data in clinical datasets, registries and randomized clinical trials.
COVID-19 Vaccination for Immunosuppressed Patients: From Guidance to Advocacy
State-level wins that ensure immunosuppressed patients can access COVID-19 vaccination show the power of coordinated efforts by volunteer leaders, staff and members to translate the ACR’s work into actionable public policy recommendations, then amplify those messages through member engagement.
Autoantibodies Against LINE-1 p40 May Be More Common in Patients with Active SLE
Researchers found nearly all systemic lupus erythematosus (SLE) patients have autoantibodies against long interspersed nuclear elements (LINE-1) p40. These findings suggest LINE-1 may be involved in the pathogenesis of SLE.
New Clinical Trials for Ustekinumab & Denosumab Biosimilars Begin Recruitment
Clinical trials of biosimilar treatments, including a phase 1 study of SB17, which is biosimilar to ustekinumab, and two phase 3 studies investigating of SB16, which is biosimilar to denosumab, are currently recruiting.
- « Previous Page
- 1
- …
- 69
- 70
- 71
- 72
- 73
- …
- 320
- Next Page »